Biocryst Pharmaceuticals (BCRX) Long-Term Investments (2010 - 2026)

Biocryst Pharmaceuticals' Long-Term Investments history runs 17 years deep, the most recent figure standing at $20.6 million for Q1 2026.

• Quarterly Long-Term Investments changed 0.1% year-over-year to $20.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.6 million (changed 0.1% YoY) and the FY2025 annual result came in at $61.2 million, up 200.96% from the prior year.
• Long-Term Investments was $20.6 million for Q1 2026 at Biocryst Pharmaceuticals, down from $61.2 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $64.3 million in Q2 2024 and bottomed at $3.4 million in Q1 2023.
• A 5-year average of $26.3 million and a median of $20.4 million in 2024 frame the typical range for Long-Term Investments.
• Annual changes were most pronounced in 2024 — Long-Term Investments jumped 1766.97% — and 2025, when it sank 84.29%.
• Biocryst Pharmaceuticals' Long-Term Investments stood at $18.1 million in 2022, then slumped by 80.94% to $3.4 million in 2023, then jumped by 489.93% to $20.3 million in 2024, then jumped by 200.96% to $61.2 million in 2025, then slumped by 66.37% to $20.6 million in 2026.
• Business Quant data shows BCRX's Long-Term Investments at $20.6 million in Q1 2026, $61.2 million in Q4 2025, and $39.7 million in Q3 2025.